In this special edition of the View, Dr. Eagle summarizes the top science that will be presented at TCT 2023 from October 23rd to October 26th in San Francisco.  

Dr. Eagle shares some of the trials that have captured attention, including: Four Year Outcomes from the EVOLUT Low Risk Trial, Five-Year Clinical and Echocardiographic Outcomes from the PARTNER 3 Low Risk Randomized Trial, Less-Than One-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug Eluting Stent Implantation for Acute Coronary Syndrome, TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement, and Individual Patient Data Pooled Analysis of Endovascular Ultrasound Renal Denervation.  

These trials hold significant promise for advancing the field of interventional cardiology, of Eagle’s Eye View looks forward to reviewing the results at TCT 2023.   

There will be daily updates giving more details on these trials and more. 

 Subscribe to Eagle’s Eye View